Chromatin immunoprecipitation-sequencing predicts p300 binding sites in the MCF7 human breast cancer cell line Corrigendum in /10.3892/ijmm.2016.2642

Wang,Xiemei; Li,Shaolin

doi:10.3892/ijmm.2015.2081

Chromatin immunoprecipitation-sequencing predicts p300 binding sites in the MCF7 human breast cancer cell line

Corrigendum in: /10.3892/ijmm.2016.2642

Authors:
- Xiemei Wang
- Shaolin Li
View Affiliations

Affiliations: Department of Radiation Medicine and Tumor Research, Chongqing Medical University, Chongqing 400016, P.R. China
Published online on: January 27, 2015 https://doi.org/10.3892/ijmm.2015.2081
Pages: 973-978

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to identify the distribution characters of p300 binding sites in estradiol (E2) stimulated MCF7 cell lines and controls, and to study the roles of transcriptional coactivator p300 in the tumorigenesis and progression of various human cancers following E2 stimulation. The chromatin immunoprecipitation followed by sequencing data of GSES9623 was downloaded from the Gene Expression Omnibus database, including breast cancer data of GSM986085 and control data of GSM986087. MACS peak‑calling software was employed to identify the p300‑bound sites in the two groups. The differential target genes of p300‑bound sites were further analyzed and the concordant factors were predicted. The Gene Ontology (GO) was used to conduct functional enrichment analysis. There were 32,249 p300 binding sites identified in the E2 stimulation group and 43,156 in the control group. GO enrichment analysis of the target genes showed that p300‑regulated target genes mainly participated in the neural cell differentiation‑associated biology process; while in the E2 stimulation group, partial functions of the target genes had changed. A total of 24,899 differential p300‑bound sites of the two groups were identified and GO enrichment analysis demonstrated that E2 stimulation changed p300 binding sites, but did not influence the regulatory function of p300. The effect of E2 in the MCF7 cells suggested that E2 affected the binding affinity of DNA and transcription factors in a large scale. By analyzing the concordant factors, several important factors were discovered, such as BRCA1 and ESR1. Overall, the results of the present study suggested an association between p300 and carcinogenic genes. This may provide theoretical guidance for cancer therapy.

View Figures

View References

1	DeSantis C, Siegel R, Bandi P and Jemal A: Breast cancer statistics, 2011. CA Cancer J Clin. 61:409–418. 2011. View Article : Google Scholar : PubMed/NCBI
2	Hortobagyi GN: Developments in chemotherapy of breast cancer. Cancer. 88:3073–3079. 2000. View Article : Google Scholar : PubMed/NCBI
3	Esteva FJ, Valero V, Pusztai L, Boehnke-Michaud L, Buzdar AU and Hortobagyi GN: Chemotherapy of metastatic breast cancer: what to expect in 2001 and beyond. Oncologist. 6:133–146. 2001. View Article : Google Scholar : PubMed/NCBI
4	Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B and Senn HJ: Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 22:1736–1747. 2011. View Article : Google Scholar : PubMed/NCBI
5	Dranoff G: Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer. 4:11–22. 2004. View Article : Google Scholar : PubMed/NCBI
6	Ben-Baruch A: Host microenvironment in breast cancer development: inflammatory cells, cytokines and chemokines in breast cancer progression: reciprocal tumor-microenvironment interactions. Breast Cancer Res. 5:31–36. 2003. View Article : Google Scholar : PubMed/NCBI
7	May D, Blow MJ, Kaplan T, et al: Large-scale discovery of enhancers from human heart tissue. Nat Genet. 44:89–93. 2012. View Article : Google Scholar
8	Visel A, Blow MJ, Li Z, et al: ChIP-seq accurately predicts tissue-specific activity of enhancers. Nature. 457:854–858. 2009. View Article : Google Scholar : PubMed/NCBI
9	Marek R, Coelho CM, Sullivan RK, et al: Paradoxical enhancement of fear extinction memory and synaptic plasticity by inhibition of the histone acetyltransferase p300. J Neurosci. 31:7486–7491. 2011. View Article : Google Scholar : PubMed/NCBI
10	Xiao XS, Cai MY, Chen JW, et al: High Expression of p300 in Human Breast Cancer Correlates with Tumor Recurrence and Predicts Adverse Prognosis. Chin J Cancer Res. 23:201–207. 2011. View Article : Google Scholar : PubMed/NCBI
11	Wang J, Xiao X, Zhang Y, et al: Simultaneous modulation of COX-2, p300, Akt, and Apaf-1 signaling by melatonin to inhibit proliferation and induce apoptosis in breast cancer cells. J Pineal Res. 53:77–90. 2012. View Article : Google Scholar : PubMed/NCBI
12	Park PJ: ChIP-seq: advantages and challenges of a maturing technology. Nat Rev Genet. 10:669–680. 2009. View Article : Google Scholar : PubMed/NCBI
13	Theodorou V, Stark R, Menon S and Carroll JS: GATA3 acts upstream of FOXA1 in mediating ESR1 binding by shaping enhancer accessibility. Genome Res. 23:12–22. 2013. View Article : Google Scholar :
14	Langmead B, Trapnell C, Pop M and Salzberg SL: Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol. 10:R252009. View Article : Google Scholar : PubMed/NCBI
15	Li H, Handsaker B, Wysoker A, et al: The Sequence Alignment/Map format and SAMtools. Bioinformatics. 25:2078–2079. 2009. View Article : Google Scholar : PubMed/NCBI
16	Zhu LJ, Gazin C, Lawson ND, et al: ChIPpeakAnno: a Bioconductor package to annotate ChIP-seq and ChIP-chip data. BMC Bioinformatics. 11:2372010. View Article : Google Scholar : PubMed/NCBI
17	Zheng Q and Wang XJ: GOEAST: a web-based software toolkit for Gene Ontology enrichment analysis. Nucleic Acids Res. 36:W358–W363. 2008. View Article : Google Scholar : PubMed/NCBI
18	Garcia-Alcalde F, Okonechnikov K, Carbonell J, et al: Qualimap: evaluating next-generation sequencing alignment data. Bioinformatics. 28:2678–2679. 2012. View Article : Google Scholar : PubMed/NCBI
19	Wilkinson L and Friendly M: The history of the cluster heat map. Am Stat. 63:2009
20	Vo N and Goodman RH: CREB-binding protein and p300 in transcriptional regulation. J Biol Chem. 276:13505–13508. 2001. View Article : Google Scholar : PubMed/NCBI
21	Bandyopadhyay D, Okan NA, Bales E, Nascimento L, Cole PA and Medrano EE: Down-regulation of p300/CBP histone acetyltransferase activates a senescence checkpoint in human melanocytes. Cancer Res. 62:6231–6239. 2002.PubMed/NCBI
22	Li M, Luo RZ, Chen JW, et al: High expression of transcriptional coactivator p300 correlates with aggressive features and poor prognosis of hepatocellular carcinoma. J Transl Med. 9:52011. View Article : Google Scholar : PubMed/NCBI
23	Robertson G, Hirst M, Bainbridge M, et al: Genome-wide profiles of STAT1 DNA association using chromatin immuno-precipitation and massively parallel sequencing. Nat Methods. 4:651–657. 2007. View Article : Google Scholar : PubMed/NCBI
24	Zhang Q, Fan H, Shen J, Hoffman RM and Xing HR: Human breast cancer cell lines co-express neuronal, epithelial, and melanocytic differentiation markers in vitro and in vivo. PLoS One. 5:e97122010. View Article : Google Scholar : PubMed/NCBI
25	Sloan EK, Priceman SJ, Cox BF, et al: The sympathetic nervous system induces a metastatic switch in primary breast cancer. Cancer Res. 70:7042–7052. 2010. View Article : Google Scholar : PubMed/NCBI
26	Dakhova O, Ozen M, Creighton CJ, et al: Global gene expression analysis of reactive stroma in prostate cancer. Clin Cancer Res. 15:3979–3989. 2009. View Article : Google Scholar : PubMed/NCBI
27	Van Swearingen AE, Sanchez CL, Frisbee SM, et al: Estradiol replacement enhances cocaine-stimulated locomotion in female C57BL/6 mice through estrogen receptor alpha. Neuropharmacology. 72:236–249. 2013. View Article : Google Scholar : PubMed/NCBI
28	Grimstad IA: Direct evidence that cancer cell locomotion contributes importantly to invasion. Exp Cell Res. 173:515–523. 1987. View Article : Google Scholar : PubMed/NCBI
29	Nitta H, Wada Y, Kawano Y, et al: Enhancement of human cancer cell motility and invasiveness by anaphylatoxin C5a via aberrantly expressed C5a receptor (CD88). Clin Cancer Res. 19:2004–2013. 2013. View Article : Google Scholar : PubMed/NCBI
30	Hein S, Muller V, Kohler N, et al: Biologic role of activated leukocyte cell adhesion molecule overexpression in breast cancer cell lines and clinical tumor tissue. Breast Cancer Res Treat. 129:347–360. 2011. View Article : Google Scholar
31	Ariazi EA, Clark GM and Mertz JE: Estrogen-related receptor alpha and estrogen-related receptor gamma associate with unfa-vorable and favorable biomarkers, respectively, in human breast cancer. Cancer Res. 62:6510–6518. 2002.PubMed/NCBI
32	Riggins RB, Mazzotta MM, Maniya OZ and Clarke R: Orphan nuclear receptors in breast cancer pathogenesis and therapeutic response. Endocr Relat Cancer. 17:R213–R231. 2010. View Article : Google Scholar : PubMed/NCBI
33	Stein RA: Memory transience, medical history and insurance. Int J Clin Pract. 62:850–851. 2008. View Article : Google Scholar : PubMed/NCBI
34	Stein RA, Gaillard S and McDonnell DP: Estrogen-related receptor alpha induces the expression of vascular endothelial growth factor in breast cancer cells. J Steroid Biochem Mol Biol. 114:106–112. 2009. View Article : Google Scholar : PubMed/NCBI
35	Salzman J, Marinelli RJ, Wang PL, et al: ESRRA-C11orf20 is a recurrent gene fusion in serous ovarian carcinoma. PLoS Biol. 9:e10011562011. View Article : Google Scholar : PubMed/NCBI
36	Lupien M, Eeckhoute J, Meyer CA, et al: FoxA1 translates epigenetic signatures into enhancer-driven lineage-specific transcription. Cell. 132:958–970. 2008. View Article : Google Scholar : PubMed/NCBI
37	Eeckhoute J, Keeton EK, Lupien M, Krum SA, Carroll JS and Brown M: Positive cross-regulatory loop ties GATA-3 to estrogen receptor alpha expression in breast cancer. Cancer Res. 67:6477–6483. 2007. View Article : Google Scholar : PubMed/NCBI
38	Mullan PB, Quinn JE and Harkin DP: The role of BRCA1 in transcriptional regulation and cell cycle control. Oncogene. 25:5854–5863. 2006. View Article : Google Scholar : PubMed/NCBI
39	Gorski JJ, Kennedy RD, Hosey AM and Harkin DP: The complex relationship between BRCA1 and ERalpha in hereditary breast cancer. Clin Cancer Res. 15:1514–1518. 2009. View Article : Google Scholar : PubMed/NCBI
40	Jeffy BD, Hockings JK, Kemp MQ, et al: An estrogen receptor-alpha/p300 complex activates the BRCA-1 promoter at an AP-1 site that binds Jun/Fos transcription factors: repressive effects of p53 on BRCA-1 transcription. Neoplasia. 7:873–882. 2005. View Article : Google Scholar : PubMed/NCBI